MoonLake Immunotherapeutics (MLTX) Assets Average (2021 - 2026)

MoonLake Immunotherapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $412.4 million for Q1 2026.

• On a quarterly basis, Assets Average fell 16.62% year-over-year to $412.4 million in Q1 2026; TTM through Mar 2026 was $412.4 million, a 16.62% decrease from a year earlier, with the FY2025 full-year figure at $451.2 million, down 10.17% from the prior year.
• Assets Average slipped to $412.4 million in Q1 2026 per MLTX's latest filing, from $419.4 million in the prior quarter.
• Across five years, Assets Average topped out at $554.5 million in Q2 2024 and bottomed at $71.8 million in Q1 2023.
• The 5-year median for Assets Average is $437.2 million (2025), against an average of $365.6 million.
• Across the five-year window, Assets Average sank 40.37% in 2023 and soared 659.3% in 2024, its largest moves.
• Year by year, Assets Average stood at $82.7 million in 2022, then soared by 520.64% to $513.4 million in 2023, then dropped by 2.98% to $498.1 million in 2024, then dropped by 15.8% to $419.4 million in 2025, then declined by 1.66% to $412.4 million in 2026.
• Per Business Quant, the three latest MLTX Assets Average figures stand at $412.4 million (Q1 2026), $419.4 million (Q4 2025), and $437.2 million (Q3 2025).